Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer (Q91926086)
Jump to navigation
Jump to search
scientific article published on 26 February 2019
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer |
scientific article published on 26 February 2019 |
Statements
Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer (English)
Xinyi Chen
Yonghai Guo
Tao Ouyang
Jinfeng Li
Tianfeng Wang
Zhaoqing Fan
Tie Fan
Benyao Lin
26 February 2019